Similar to therapeutic agents targeting PD-1 and PD-L1, their effects on CTLA-4 have been developed as nanotherapeutics by conjugating the effective drugs to nanocarriers, particularly those with thermal conversion properties, because hyperthermia-mediated tumor ablation induces immunogenic cell death [26]. This evidence concerns the gene PDCD1 and neoplasm.